Abstract:
Objective: To observe the predictive efficacy of dual-phase (venous and arterial) dual-energy computed tomography (CT) quantitative parameters for the initial recurrence risk stratification of papillary thyroid carcinoma (PTC). Methods: We enrolled 114 PTC patients who underwent surgery between January 2022 and June 2025. Based on the initial recurrence risk assessment, patients were divided into low-risk (n = 84) and medium-high-risk (n = 30) groups. Clinical data and dual-phase dual-energy CT parameters were compared between the two groups. Univariate and multivariate logistic regression analyses were performed to assess the relationship between dual-phase dual-energy CT quantitative parameters and initial recurrence risk stratification of PTC. A nomogram was constructed using R software, and the predictive efficacy for initial recurrence risk stratification was determined by plotting receiver operating characteristic (ROC), calibration, and clinical decision curves. Results: Compared with the low-risk group, the long and short diameters of the lesions in the medium-high-risk group were longer (
P < 0.05), and the iodine concentration (IC) in the arterial phase, effective atomic number (Zeff) in the arterial phase, normalized IC (NIC) in the venous phase, and normalized Zeff (NZeff) in the venous phase were lower. Multivariate logistic regression analysis revealed that arterial-phase IC, venous-phase NIC, and venous-phase NZeff were independent risk factors of intermediate-to-high initial recurrence. The combined model demonstrated an area under the curve (AUC) of 0.923 (95% confidence interval CI: 0.851–0.980), with a sensitivity of 84.8% and specificity of 81.8%. Hosmer-Lemeshow test results revealed \chi^2 = 1.414 and P = 0.994, with no significant fitting issues. The clinical decision curve established a reasonable probability threshold range of 0–0.6. Conclusion: The combined predictive model constructed with quantitative parameters of dual-phase dual-energy CT, specifically arterial-phase IC, venous-phase NIC, and venous-phase NZ
eff, can enhance the preoperative predictive efficacy for initial recurrence risk stratification in PTC, providing a crucial radiological reference for personalized clinical treatment planning and prognosis assessment.